Abstract

BackgroundSyndesmophyte formation in ankylosing spondylitis (AS) is still insufficiently understood. Previous studies have suggested an association between MRI vertebral edge inflammation (VEI) and vertebral edge fat deposition (VEFD) and the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
OP0218 Erosions and Sclerosis, but not Squaring Predict the Development of New Syndesmophytes: A 12-Year Longitudinal Analysis
F Van Den Bosch ... R Landewé
Annals of the Rheumatic Diseases | VOL. 72
F Van Den Bosch, et. al.F Van Den Bosch ... R Landewé
01 Jun 2013
Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study
Astrid Van Tubergen ... Désirée Van Der Heijde
Annals of the Rheumatic Diseases | VOL. 71
Astrid Van Tubergen, et. al.Astrid Van Tubergen ... Désirée Van Der Heijde
11 Oct 2011
The predictors of development of new syndesmophytes in female patients with ankylosing spondylitis
Ky Kang ... Jh Ju
Scandinavian Journal of Rheumatology | VOL. 44
Ky Kang, et. al.Ky Kang ... Jh Ju
29 Oct 2014
OP0172 Inflammation and fatty degeneration are of similar importance for new bone formation in patients with ankylosing spondylitis treated with infliximab or other anti-TNF agents over 5 years
P Emery ... J Callhoff
Annals of the Rheumatic Diseases | VOL. 71
P Emery, et. al.P Emery ... J Callhoff
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers